A bombshell report published June 23 set off a frenzy online, with social media users and political observers alike asking the same question: Is President Donald Trump taking an experimental weight loss drug?
The story originated as a STAT+ exclusive, reported by Lizzy Lawrence, who leads the publication’s FDA coverage. Lawrence revealed that pharmaceutical giant Eli Lilly and the Food and Drug Administration had quietly granted a single individual access to retatrutide — a not-yet-approved weight loss medication that has shown bariatric-surgery-level results in clinical trials — through a federal program designed for patients facing serious or immediately life-threatening medical conditions. The details that emerged made it nearly impossible for the internet not to connect the dots.
The Report That Sparked It All
Three sources who spoke to Lawrence on condition of anonymity, citing fear of reprisals, said the individual who received the drug was a 79-year-old man when the compassionate use request was submitted in April. The sources also noted that the application drew the attention of top health officials, signaling the recipient was someone with considerable influence. Lawrence wrote that, given those details, she asked the White House directly whether the patient was Trump — who turned 80 on June 14 — and said she did not receive a direct answer.
Millions of Americans living with obesity have been watching retatrutide’s development closely. The FDA’s compassionate use program is specifically reserved for patients with serious and immediately life-threatening medical issues who need access to experimental treatments when standard options fall short. Yet some Americans have not waited for official channels, instead racing to acquire the drug through what Lawrence’s report described as sketchy means ahead of FDA approval.
The timing and demographics of the compassionate use request aligned precisely with Trump’s profile in April, when he was 79 years old. The fact that it drew scrutiny from top health officials only amplified speculation that the recipient was someone exceptionally well connected. Lawrence noted the peculiar nature of the application in her reporting, questioning why someone would receive such extraordinary access to a drug still undergoing clinical trials.
The White House Fires Back
The administration was quick to respond — and pulled no punches. The White House rapid response team posted a statement on X dismissing the report entirely. The statement read, “No, it wasn’t President Trump — and you people are truly sick and deranged.” Trump himself had not directly addressed the newest report as of June 24.
This is not the first time questions about the president and weight loss medications have surfaced. Back in January, when the New York Times asked Trump whether he had used GLP-1 drugs like Wegovy or Ozempic, he responded plainly that he had not, adding, “I probably should.” The statement resurfaced and gained renewed attention on social media following the recent revelations.
What Trump’s Doctor Has Said
White House physician Sean Barbabella issued the most recent health memorandum on Trump on May 29, following a routine check-up. At that visit, Trump weighed 238 pounds. The report noted bruising on Trump’s hands and said it resulted from “minor soft tissue irritation related to frequent handshaking.”
In the same memo, Barbabella concluded that Trump “remains in excellent health, demonstrating strong cardiac, pulmonary, neurological, and overall physical function,” and determined the president possesses complete capability to perform every responsibility of his position. The physician also stated that Trump’s rigorous daily routine of important meetings, official appearances, and consistent exercise helps maintain his health, noting his mental and physical abilities remain at peak levels.
Dr. Mehmet Oz, the administrator for the Centers for Medicare and Medicaid Services, was among those with whom Trump discussed his feelings ahead of his milestone birthday. Trump said he had conflicted feelings about reaching 80 and told Oz he didn’t want birthday wishes because he wasn’t pleased about the occasion, adding that it was a number he never expected to think much about and didn’t like, though he had reached it nonetheless.
He celebrated turning 80 on June 14 with a UFC fight held on the White House lawn, an event that doubled as part of the broader festivities surrounding the upcoming 250th anniversary of American independence.
A President in the Public Eye
Just days before the drug report broke, Trump was on the world stage at the G7 Summit on June 17 in Evian-les-Bains, France, where he participated in a working session on promoting economic growth alongside leaders including German Chancellor Friedrich Merz. The president’s physical appearance and stamina remain under constant public scrutiny, particularly as he carries out the demanding schedule of the nation’s oldest serving president.
Retatrutide remains under review and has not yet received full FDA approval, though its clinical profile has generated significant enthusiasm in the medical community and among the estimated millions of Americans waiting for it. Whether or not the compassionate use recipient turns out to be Trump, the episode has reignited a national conversation about the president’s health, the politics of pharmaceutical access, and the lengths to which public curiosity about a sitting president can reach. The White House’s vehement denial has done little to quiet the speculation, and the identity of the 79-year-old man who received extraordinary access to one of the most anticipated drugs in modern medicine remains officially unconfirmed.